KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pacira BioSciences (PCRX) EBITDA (2016 - 2026)

Pacira BioSciences has reported EBITDA over the past 17 years, most recently at $6.9 million for Q1 2026.

  • For Q1 2026, EBITDA rose 246.83% year-over-year to $6.9 million; the TTM value through Mar 2026 reached $24.1 million, up 128.49%, while the annual FY2025 figure was $19.2 million, 126.16% up from the prior year.
  • EBITDA for Q1 2026 was $6.9 million at Pacira BioSciences, up from $2.3 million in the prior quarter.
  • Over five years, EBITDA peaked at $39.9 million in Q2 2023 and troughed at -$139.5 million in Q3 2024.
  • A 5-year average of $5.9 million and a median of $13.2 million in 2024 define the central range for EBITDA.
  • On a YoY basis, EBITDA climbed as much as 527.43% in 2024 and fell as far as 887.35% in 2024.
  • Year by year, EBITDA stood at -$9.9 million in 2022, then skyrocketed by 435.27% to $33.2 million in 2023, then decreased by 25.52% to $24.7 million in 2024, then plummeted by 90.53% to $2.3 million in 2025, then surged by 194.96% to $6.9 million in 2026.
  • Business Quant data shows EBITDA for PCRX at $6.9 million in Q1 2026, $2.3 million in Q4 2025, and $6.4 million in Q3 2025.